Literature DB >> 3542319

In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production.

P L Meroni, W Barcellini, D Frasca, C Sguotti, M O Borghi, G De Bartolo, G Doria, C Zanussi.   

Abstract

The effect of thymopentin (TP-5) treatment on lymphocyte immune functions has been investigated in immunocompromised aged subjects. TP-5 was able to improve the cutaneous delayed hypersensitivity (CDH) to recall antigens and the proliferative response to phytohemagglutinin (PHA), concanavalin A, and Pokeweed (PWM) as well as the PHA-induced interleukin-2 (Il-2) production. On the other hand, no detectable changes were induced by TP-5 treatment either on PWM-induced immunoglobulin synthesis or on lymphocyte subsets identified by monoclonal antibodies. Our results suggest that the enhancement of Il-2 synthesis might be a crucial mechanism of the immunopharmacological action of TP-5 in aging humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3542319     DOI: 10.1016/0090-1229(87)90002-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  5 in total

Review 1.  Immunodeficiency of aging.

Authors:  E A Burns; J S Goodwin
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 4.271

2.  Thymopentin reduces the susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T-cell subsets.

Authors:  E Cillari; S Milano; M Dieli; F Arcoleo; R Perego; F Leoni; G Gromo; A Severn; F Y Liew
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

3.  Effect of synthetic thymic humoral factor (THF-gamma 2) on T cell activities in immunodeficient ageing mice.

Authors:  C Goso; D Frasca; G Doria
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

4.  Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.

Authors:  K H Hsieh; M F Shaio; T N Liao
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 5.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.